Processa Pharmaceuticals, Inc.
PCSA
$2.55
-$0.01-0.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.26% | 12.64% | -38.79% | -3.87% | 19.38% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 50.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -152.41% | 44.42% | -9.57% | 41.24% | 0.74% |
| Change in Net Operating Assets | 267.70% | -126.14% | 1,081.22% | -148.28% | 176.90% |
| Cash from Operations | 16.75% | -53.47% | 16.83% | -21.45% | 37.61% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -192.31% | 13.33% | 0.00% | -7.14% |
| Issuance of Common Stock | 4.17% | -54.75% | 42.39% | 707.90% | -41.01% |
| Repurchase of Common Stock | -- | 100.00% | -542.86% | -366.67% | 91.89% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4.30% | -54.74% | 42.26% | 710.01% | -40.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.81% | -115.55% | 136.82% | 200.33% | 36.56% |